| Bolstering Ethical Management and Minimizing Legal Risks in Korea’s Pharma, Biotech, and MedTech Industries
| Led by JaeHyun Lee, Formerly of Kim & Chang, the Team Advances Ethical Compliance Through Policy Monitoring and Regulatory Reporting
| Proven Demand from Leading Domestic Companies; Strengthened Team Poised to Deliver Essential Industry Service
| Supporting Clients’ Business Stability While Driving Ethical Culture and Global-Standard Transparency Across the Industry
From left, JaeHyun Lee, Head of JNPMEDI's Compliance Service Team, and HyunKwon Choi, Team Leader. (Photo courtesy of JNPMEDI)
JNPMEDI takes the lead in fostering an ethical management culture across the pharmaceutical, biotech, and medical device industries.
JNPMEDI (CEO KwunHo Jeong), an AI-powered clinical trial consulting firm, announced on the 13th the official launch of its dedicated Compliance Service Team to strengthen regulatory support and minimize legal risks for companies in the healthcare sector. The new team is led by JaeHyun Lee, formerly of Kim & Chang’s Healthcare & Compliance Team, and HyunKwon Choi, a former QA lead at Pfizer HQ.
Companies in Korea’s pharmaceutical, biotech, and medical device sectors operate under increasingly complex regulations concerning R&D and operational expenditures. With the government’s focus on enhancing distribution transparency and eliminating illegal kickbacks, compliance with relevant laws and guidelines is becoming more critical.
In February, the Ministry of Health and Welfare disclosed expenditure reports on economic benefits submitted by pharmaceutical and medical device companies, underscoring the need for companies to build stronger compliance systems and improve transparency.
Preparing reports for regulatory authorities—such as expenditure disclosures—has become a major challenge. While sponsor companies are responsible for submission, they often rely on CROs for cost data, making it difficult to ensure accuracy and compliance. Many CROs fall short of producing the advanced reports required by regulators.
JNPMEDI’s Compliance Service Team helps companies navigate these challenges and manage legal risks. The team continuously monitors policy changes, clarifies legal standards for exceptional R&D expenditures, and supports detailed classification to distinguish lawful from unlawful spending. It also assists in preparing regulatory reports and improving internal documentation to prevent potential violations.
Reports prepared by the new team are deemed complete and compliant enough to be submitted directly to regulators, easing the reporting burden and addressing key pain points for companies in the pharmaceutical, biotech, and medical device sectors.
JNPMEDI has already demonstrated the value of its compliance services by working with leading domestic companies. With this expanded team, it aims to become an essential partner for companies struggling with regulatory demands, further promoting transparency and ethical practices in the healthcare sector.
"Given the ongoing kickback issues in the healthcare industry, clearly distinguishing between legitimate R&D spending and unlawful practices is a critical challenge," said JaeHyun Lee, Head of JNPMEDI’s Compliance Service Team. "As Korean healthcare companies face increasing demands for transparency and compliance, this team was launched to help them respond proactively and establish robust compliance systems."
He added, "JNPMEDI will continue to provide comprehensive support to ensure business stability and sustainable growth for our clients, while helping the broader healthcare industry build an ethical culture and achieve global standards of transparency."
| Bolstering Ethical Management and Minimizing Legal Risks in Korea’s Pharma, Biotech, and MedTech Industries
| Led by JaeHyun Lee, Formerly of Kim & Chang, the Team Advances Ethical Compliance Through Policy Monitoring and Regulatory Reporting
| Proven Demand from Leading Domestic Companies; Strengthened Team Poised to Deliver Essential Industry Service
| Supporting Clients’ Business Stability While Driving Ethical Culture and Global-Standard Transparency Across the Industry
JNPMEDI takes the lead in fostering an ethical management culture across the pharmaceutical, biotech, and medical device industries.
JNPMEDI (CEO KwunHo Jeong), an AI-powered clinical trial consulting firm, announced on the 13th the official launch of its dedicated Compliance Service Team to strengthen regulatory support and minimize legal risks for companies in the healthcare sector. The new team is led by JaeHyun Lee, formerly of Kim & Chang’s Healthcare & Compliance Team, and HyunKwon Choi, a former QA lead at Pfizer HQ.
Companies in Korea’s pharmaceutical, biotech, and medical device sectors operate under increasingly complex regulations concerning R&D and operational expenditures. With the government’s focus on enhancing distribution transparency and eliminating illegal kickbacks, compliance with relevant laws and guidelines is becoming more critical.
In February, the Ministry of Health and Welfare disclosed expenditure reports on economic benefits submitted by pharmaceutical and medical device companies, underscoring the need for companies to build stronger compliance systems and improve transparency.
Preparing reports for regulatory authorities—such as expenditure disclosures—has become a major challenge. While sponsor companies are responsible for submission, they often rely on CROs for cost data, making it difficult to ensure accuracy and compliance. Many CROs fall short of producing the advanced reports required by regulators.
JNPMEDI’s Compliance Service Team helps companies navigate these challenges and manage legal risks. The team continuously monitors policy changes, clarifies legal standards for exceptional R&D expenditures, and supports detailed classification to distinguish lawful from unlawful spending. It also assists in preparing regulatory reports and improving internal documentation to prevent potential violations.
Reports prepared by the new team are deemed complete and compliant enough to be submitted directly to regulators, easing the reporting burden and addressing key pain points for companies in the pharmaceutical, biotech, and medical device sectors.
JNPMEDI has already demonstrated the value of its compliance services by working with leading domestic companies. With this expanded team, it aims to become an essential partner for companies struggling with regulatory demands, further promoting transparency and ethical practices in the healthcare sector.
"Given the ongoing kickback issues in the healthcare industry, clearly distinguishing between legitimate R&D spending and unlawful practices is a critical challenge," said JaeHyun Lee, Head of JNPMEDI’s Compliance Service Team. "As Korean healthcare companies face increasing demands for transparency and compliance, this team was launched to help them respond proactively and establish robust compliance systems."
He added, "JNPMEDI will continue to provide comprehensive support to ensure business stability and sustainable growth for our clients, while helping the broader healthcare industry build an ethical culture and achieve global standards of transparency."